Market Access News | pharmaphorum

News

AZ halts UK investment, and Lilly, Sanofi follow suit

After MSD's bombshell retreat from a big UK investment plan, AstraZeneca, Lilly, and Sanofi are also pressing pause on new projects.

News

Reaction to MSD's UK exit as government tries to renew talks

The UK government is reported to be trying to restart talks over drug pricing and rebates after MSD's shock decision to scrap a £1bn investment spend.

News

Intercept pulls Ocaliva off the market in the US

Alfasigma's $800m buyout of Intercept is starting to look like a poor bet as its only product, Ocaliva, is pulled from the market.

News

J&J claims FDA okay for bladder cancer drug TAR-200

Johnson & Johnson has brought its bladder cancer drug TAR-200 to the US market, a year after its prospects were dented by a negative phase 3 readout.

News

Pharma says UK is 'tumbling down' rankings for investment

The UK is losing out to competitors in attracting investment in R&D, clinical trials, and capital projects, says a report from the ABPI pharma group.

News

Fresh blow to UK life sciences as MSD abandons £1bn project

In a blow to UK life science ambitions, MSD has scrapped a £1bn expansion of its operations in the country, saying it does not value innovation.

AZ halts UK investment, and Lilly, Sanofi follow suit

Reaction to MSD's UK exit as government tries to renew talks

Intercept pulls Ocaliva off the market in the US

J&J claims FDA okay for bladder cancer drug TAR-200

Pharma says UK is 'tumbling down' rankings for investment

Fresh blow to UK life sciences as MSD abandons £1bn project

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks